Related Experiment Video

Updated: Jun 1, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes

Yutaro Nagano1, Hiroshi Yokouchi2, Ryota Saito3

  • 1Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Cancer Science
|May 31, 2026
PubMed

Insights

Afatinib and osimertinib show similar survival for non-small cell lung cancer (NSCLC) with uncommon EGFR mutations. Treatment effectiveness varies by mutation subtype, and subsequent immune checkpoint inhibitors offer limited benefit.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations presents heterogeneous clinical challenges.
  • Optimal first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) and the role of immune checkpoint inhibitors (ICIs) remain unclear for these patients.

Purpose of the Study:

  • To compare the efficacy and safety of first-line afatinib versus osimertinib in advanced non-squamous NSCLC patients with uncommon EGFR mutations.
  • To evaluate the impact of subsequent therapies, including ICI-based regimens, after initial EGFR-TKI treatment.

Main Methods:

  • Multicenter retrospective cohort study of 162 patients with advanced or recurrent non-squamous NSCLC and uncommon EGFR mutations (excluding exon 20 insertions and de novo T790M).
  • Patients received either first-line afatinib or osimertinib between January 2015 and January 2024.
  • Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances; treatment patterns and outcomes were analyzed.

Main Results:

  • Weighted analyses revealed no significant differences in time to treatment failure (HR 1.04) or overall survival (HR 1.34) between afatinib and osimertinib.
  • Afatinib was associated with higher response rates but more frequent adverse events requiring dose reduction.
  • Subgroup analyses indicated differential effects: osimertinib favored L861X mutations, while afatinib favored compound mutations.
  • Subsequent ICI plus platinum doublet therapy showed comparable outcomes to platinum doublet alone in 56 patients.

Conclusions:

  • Afatinib and osimertinib offer comparable survival outcomes as first-line treatments for NSCLC with uncommon EGFR mutations.
  • Treatment efficacy is influenced by specific molecular subtypes.
  • Subsequent immune checkpoint inhibitor-based regimens appear to provide limited additional survival benefit.
Keywords:
afatinibepidermal growth factor receptornon–small cell lung cancerosimertinibuncommon mutations

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...